EyePoint, Inc.
US ˙ NasdaqGM ˙ US30233G2093

SecurityEYPT / EyePoint, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership1,905,875 shares
Latest Disclosed Value $ 24,566,729
Citadel Advisors Llc ownership in EYPT / EyePoint, Inc.

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 1,905,875 shares of EyePoint, Inc. (US:EYPT) valued at $24,566,729 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 0 shares of EyePoint, Inc.. The current value of the position is $23,518,498 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (EYPT) in the form of stock options. The firm currently holds call options representing 99,400 of underlying shares valued at $1,281,266 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

EYPT / EyePoint, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F EYEPOINT COM NEW 30233G209 1,905,875 1,905,875 24,567 0.0040
2026-02-17 2025-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -2,135,389 -100.00 0 -100.00
2025-11-14 2025-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 2,135,389 -208,821 -8.91 30,408 37.84 0.0046
2025-08-14 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 2,344,210 58,121 2.54 22,059 78.04 0.0038
2025-05-15 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 2,286,089 -180,777 -7.33 12,391 -32.58 0.0023
2025-02-14 2024-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 2,466,866 1,059,513 75.28 18,378 63.45 0.0032
2024-11-14 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,407,353 52,821 3.90 11,245 -4.58 0.0022
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,354,532 -20,985 -1.53 11,784 -58.55 0.0024
2024-05-15 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,375,517 148,239 12.08 28,432 0.24 0.0055
2024-02-14 2023-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,227,278 168,231 15.89 28,362 235.21 0.0057
2023-11-14 2023-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,059,047 211,284 24.92 8,462 14.73 0.0018
2023-08-14 2023-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 847,763 -70,253 -7.65 7,376 173.35 0.0015
2023-05-15 2023-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 918,016 359,128 64.26 2,699 37.93 0.0006
2023-02-14 2022-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 558,888 120,016 27.35 1,956 -43.65 0.0005
2022-11-14 2022-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 438,872 -602,145 -57.84 3,471 -57.63 0.0008
2022-08-15 2022-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,041,017 -429,279 -29.20 8,193 -54.14 0.0021
2022-05-16 2022-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,470,296 1,083 0.07 17,864 -0.66 0.0037
2022-02-14 2021-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,469,213 522,789 55.24 17,983 82.35 0.0037
2021-11-15 2021-09-30 13F EYEPOINT PHARMACEUTICALS Cmn 30233G209 946,424 -11,461 -1.20 9,862 14.51 0.0020
2021-08-16 2021-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 957,885 -77,719 -7.50 8,612 -18.15 0.0019
2021-05-21 2021-03-31 13F/A-1 EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,035,604 1,021,727 7,362.74 10,522 11,462.64 0.0026
2021-05-17 2021-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 1,035,604 1,021,727 10,522 0.0026
2021-02-16 2020-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 13,877 13,877 91 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F EYEPOINT COM NEW Call 99,400 57.28 1,281 11.01 n/a n/a n/a
2026-02-17 2025-12-31 13F EYEPOINT COM NEW Call 63,200 -28.34 1,155 -8.05 n/a n/a n/a
2025-11-14 2025-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 88,200 -5.67 1,256 42.78 n/a n/a n/a
2025-08-14 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 93,500 18.20 880 105.37 n/a n/a n/a
2025-05-15 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 79,100 -6.06 429 -31.74 n/a n/a n/a
2025-02-14 2024-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 84,200 -6.65 627 -12.92 n/a n/a n/a
2024-11-14 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 90,200 -9.35 721 -16.76 n/a n/a n/a
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 99,500 4.41 866 -56.07 n/a n/a n/a
2024-05-15 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 95,300 -80.89 1,970 -82.92 n/a n/a n/a
2024-02-14 2023-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 498,800 764.47 11,527 2,400.43 n/a n/a n/a
2023-11-14 2023-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 57,700 347.29 461 311.61 n/a n/a n/a
2023-08-14 2023-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 12,900 174.47 112 761.54 n/a n/a n/a
2023-05-15 2023-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 4,700 -47.78 14 -58.06 n/a n/a n/a
2023-02-14 2022-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 9,000 -56.10 32 -80.86 n/a n/a n/a
2022-11-14 2022-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 20,500 13.26 162 14.08 n/a n/a n/a
2022-08-15 2022-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 18,100 -41.61 142 -62.33 n/a n/a n/a
2022-05-16 2022-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 31,000 -53.52 377 -53.80 n/a n/a n/a
2022-02-14 2021-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 66,700 36.40 816 60.00 n/a n/a n/a
2021-11-15 2021-09-30 13F EYEPOINT PHARMACEUTICALS Cmn Call 48,900 28.35 510 48.69 n/a n/a n/a
2021-08-16 2021-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Call 38,100 7.63 343 -4.72 n/a n/a n/a
2021-05-21 2021-03-31 13F/A EYEPOINT PHARMACEUTICALS COM NEW Call 35,400 360 n/a n/a n/a
2021-05-17 2021-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Call 35,400 360 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F EYEPOINT COM NEW Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F EYEPOINT COM NEW Put 37,300 -22.13 681 -0.15 n/a n/a n/a
2025-11-14 2025-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 47,900 -23.11 682 16.38 n/a n/a n/a
2025-08-14 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 62,300 2.47 586 78.12 n/a n/a n/a
2025-05-15 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 60,800 68.89 330 22.76 n/a n/a n/a
2025-02-14 2024-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 36,000 -13.46 268 -19.28 n/a n/a n/a
2024-11-14 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 41,600 -66.10 332 -68.88 n/a n/a n/a
2024-08-14 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 122,700 40.23 1,067 -40.98 n/a n/a n/a
2024-05-15 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 87,500 92.73 1,809 72.35 n/a n/a n/a
2024-02-14 2023-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 45,400 56.01 1,049 352.16 n/a n/a n/a
2023-11-14 2023-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 29,100 298.63 233 268.25 n/a n/a n/a
2023-08-14 2023-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 7,300 151.72 64 687.50 n/a n/a n/a
2023-05-15 2023-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 2,900 -51.67 9 -61.90 n/a n/a n/a
2023-02-14 2022-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 6,000 21 n/a n/a n/a
2022-03-11 2021-09-30 13F/A EYEPOINT PHARMACEUTICALS COM NEW Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-11-15 2021-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 0 0 n/a n/a n/a
2021-08-16 2021-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW Put 43,800 -2.23 394 -13.41 n/a n/a n/a
2021-05-21 2021-03-31 13F/A EYEPOINT PHARMACEUTICALS COM NEW Put 44,800 455 n/a n/a n/a
2021-05-17 2021-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW Put 44,800 455 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.